While anti–IL-17 therapy has shown promise in psoriatic arthritis patients, these biologics can paradoxically increase intestinal inflammation in ulcerative colitis patients, limiting interest in their utility for CRC patients. This evidence concerns the gene IL17A and ulcerative colitis.